GenMark Diagnostics (NASDAQ:GNMK) released its earnings results on Monday. The medical equipment provider reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.02), Morningstar.com reports. GenMark Diagnostics had a negative net margin of 71.40% and a negative return on equity of 137.04%. The company had revenue of $18.37 million during the quarter, compared to analyst estimates of $17.92 million. GenMark Diagnostics updated its FY 2019 guidance to EPS.
Shares of GenMark Diagnostics stock traded down $0.04 on Wednesday, hitting $6.61. The company had a trading volume of 16,995 shares, compared to its average volume of 442,356. The company has a market capitalization of $343.88 million, a price-to-earnings ratio of -7.15 and a beta of 1.27. GenMark Diagnostics has a twelve month low of $3.58 and a twelve month high of $8.81. The company has a debt-to-equity ratio of 1.96, a current ratio of 3.93 and a quick ratio of 3.40. The company has a 50-day simple moving average of $6.38.
In other news, insider Hany Massarany sold 10,369 shares of the stock in a transaction on Thursday, May 30th. The shares were sold at an average price of $6.60, for a total transaction of $68,435.40. Following the completion of the sale, the insider now owns 824,951 shares of the company’s stock, valued at $5,444,676.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 35,193 shares of company stock valued at $235,548 in the last quarter. Corporate insiders own 5.24% of the company’s stock.
Several equities analysts have weighed in on GNMK shares. Canaccord Genuity reissued a “buy” rating and issued a $10.00 target price on shares of GenMark Diagnostics in a research note on Monday, July 1st. BidaskClub lowered GenMark Diagnostics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 23rd. Finally, Zacks Investment Research lowered GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Thursday, June 13th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $9.67.
About GenMark Diagnostics
GenMark Diagnostics, Inc, a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results.
See Also: Why do corrections happen?
Receive News & Ratings for GenMark Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.